Hopes that anti-tau drugs could emerge as treatments for Alzheimer’s have been dented by the failure of a phase 2b trial of J&J’s posdinemab.
Investors buy up stocks in biggest follow-on offering day in biotech history
A record-setting $3.2 billion in biotech follow-on stock offerings were sold over the last 24 hours, another indication of public investors’ appetite for the sector.


